Andere Sprachen Gossamer Bio, Inc.

Aktien

A2PCBS

US38341P1021

GOSS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
0.5484 ^USD	-8.60%		-7.05%	-39.90%

07.05.	Gossamer Bio, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
06.05.	Chiesi Farmaceutici S.P.A Gossamer Bio, Inc kündigt transformative globale Zusammenarbeit zur Entwicklung und Vermarktung von Seralutinib bei pulmonaler arterieller Hypertonie und anderen Atemwegserkrankungen an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07.06.
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference	14.05.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	10.05.
Gossamer Bio: Q1 Earnings Snapshot	07.05.
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update	07.05.
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Gossamer bio announces publication of torrey phase 2 results in the lancet respiratory medicine	06.05.
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	06.05.
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment	06.05.
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications	06.05.
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine	03.05.
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine	03.05.
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors	12.03.
Gossamer Bio Announces Board of Directors Appointments	12.03.
Gossamer Bio: Q4 Earnings Snapshot	05.03.
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	05.03.
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05.03.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08.01.
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from NASDAQ Biotechnology Index	15.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Gossamer Bio, Inc.

Aktien

A2PCBS

US38341P1021

GOSS

Andere Sprachen

Filter